• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [21894 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2005     Institute for Clinical Effectiveness and Health Policy (IECS) Radiofrequency techniques for the management of lumbar discopathy (discal nucleoplasty, percutaneous thermocoagulation, electrothermal annuloplasty)
2006     HAYES, Inc. Radiofrequency tissue volume reduction (RFTVR) for the treatment of upper airway obstruction
2007     HAYES, Inc. Radiofrequency tissue volume reduction for the treatment of upper airway obstruction
1999     Comite d'Evaluation et de Diffusion des Innovations Technologiques (CEDIT) Radiofrequency treatment for liver and osseous metastasis (systematic review, expert panel)
2004     National Institute for Clinical Excellence (NICE) Radiofrequency valvotomy for pulmonary atresia
2000     HAYES, Inc. Radiofrequency volumetric tissue reduction for the treatment of upper airway obstruction
2004     National Institute for Clinical Excellence (NICE) Radiofrequency volumetric tissue reduction for turbinate hypertrophy
2007     National Institute for Health and Care Excellence (NICE) Radiofrequency-assisted liver resection
2020     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Radiofrequency-Induced Intravesical Chemohyperthermia for Non-Muscle-Invasive Bladder Cancer
2009     Canadian Agency for Drugs and Technologies in Health (CADTH) Radioimmunotherapies for non-hodgkin lymphoma: systematic review of clinical effectiveness, cost-effectiveness, and guidelines
2009     Canadian Agency for Drugs and Technologies in Health (CADTH) Radioimmunotherapies for non-hodgkin lymphoma: systematic review of clinical effectiveness, cost-effectiveness, and guidelines
2013     HAYES, Inc. Radioiodinated metaiodobenzylguanidine (131I-MIBG) targeted radiation therapy for refractory or relapsed neuroblastoma
2003     Comite d'Evaluation et de Diffusion des Innovations Technologiques (CEDIT) Radiological bucky tables with a CCD camera - systematic review, primary research, expert panel
2001     Comite d'Evaluation et de Diffusion des Innovations Technologiques (CEDIT) Radionuclide therapy- systematic review, expert panel
1997     Comite d'Evaluation et de Diffusion des Innovations Technologiques (CEDIT) Radiosurgery (systematic review, working group, expert panel)
1997     Alberta Heritage Foundation for Medical Research (AHFMR) Radiosurgery in the treatment of malignant melanoma
2004     National Institute for Clinical Excellence (NICE) Radiotherapy for age-related macular degeneration
2003     The Swedish Council on Health Technology Assessment (SBU) Radiotherapy for cancer
1999     Healthcare Insurance Board/ College Voor Zorgverzekeringen (CVZ) Radiotherapy in bone metastasis - primary research
1996     The Swedish Council on Health Technology Assessment (SBU) Radiotherapy in Sweden [2 vols.]
2014     Agency for Healthcare Research and Quality (AHRQ) Radiotherapy treatments for head and neck cancer update
2014     Medical Services Advisory Committee (MSAC) Radium 223 for the treatment of patients with symptomatic castrate resistant prostate cancer with skeletal metastases
2014     NIHR Health Technology Assessment programme Radium-223 dichloride for treating metastatic hormone relapsed prostate cancer with bone metastases
2017     HAYES, Inc. Raindrop near vision inlay (ReVision Optics Inc.) for presbyopia
2005     Canadian Coordinating Office for Health Technology Assessment (CCOHTA) Raloxifene for primary and secondary prevention of osteoporotic fractures in postmenopausal women: a systematic review of efficacy and safety evidence
1999     ECRI Raloxifene, a selective estrogen receptor modulator [SERM] for prevention of postmenopausal osteoporosis
2015     All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Raltegravir (Isentress®)
2013     All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Raltegravir (Isentress®)
2008     All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Raltegravir (Isentress®) in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infection in treatment-experienced adult patients with evidence of HIV-1 replication despite ongoing antiretroviral therapy
2010     All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Raltegravir (Isentress®) in combination with other antiretrovirals for the treatment of HIV-1 infection in adults
2012     All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Ramipril 2.5 mg/5 ml oral solution
2014     NIHR Horizon Scanning Centre (NIHR HSC) Ramucirumab (Cyramza) in combination with docetaxel for locally advanced or metastatic non-small cell lung cancer – second line
2013     NIHR Horizon Scanning Centre (NIHR HSC) Ramucirumab for hepatocellular cancer – second line
2014     NIHR Horizon Scanning Centre (NIHR HSC) Ramucirumab for metastatic colorectal cancer – second line
2015     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Ramucirumab in combination with paclitaxel as second-line treatment for adult patients with advanced gastric or gastro-oesophageal junction carcinoma
2014     NIHR Horizon Scanning Centre (NIHR HSC) Ramucirumab in combination with paclitaxel for advanced gastric cancer and gastro-oesophageal junction adenocarcinoma after prior chemotherapy
2013     NIHR Horizon Scanning Centre (NIHR HSC) Ramucirumab monotherapy for advanced gastric cancer and gastro-oesophageal junction adenocarcinoma – after prior chemotherapy
2013     NIHR Health Technology Assessment programme Randomised Assessment of Treatment using Panel Assay of Cardiac markers - Contemporary Biomarker Evaluation (RATPAC CBE)
2006     NIHR Health Technology Assessment programme Randomised clinical trial, observational study and assessment of cost-effectiveness of the treatment of varicose veins (REACTIV trial)
2022     NIHR Health Technology Assessment programme Randomised control trial of surveillance and no surveillance for patients with Barrett's oesophagus - BOSS (Barrett's Oesophagus Surveillance Study)
2005     NIHR Health Technology Assessment programme Randomised controlled multiple treatment comparison to provide a cost-effectiveness rationale for the selection of antimicrobial therapy in acne
2017     NIHR Health Technology Assessment programme Randomised controlled trial and economic analysis of an internet-based weight management programme: POWeR+ (Positive Online Weight Reduction)
2017     NIHR Health Technology Assessment programme Randomised controlled trial and economic analysis of an internet-based weight management programme: POWeR+ (Positive Online Weight Reduction)
2014     NIHR Health Technology Assessment programme Randomised controlled trial and health economic evaluation of the impact of diagnostic testing for influenza, respiratory syncytial virus and Streptococcus pneumoniae infection on the management of acute admissions in the elderly and high-risk 18- to 64-year olds
2014     NIHR Health Technology Assessment programme Randomised controlled trial and health economic evaluation of the impact of diagnostic testing for influenza, respiratory syncytial virus and Streptococcus pneumoniae infection on the management of acute admissions in the elderly and high-risk 18- to 64-year-olds
2010     NIHR Health Technology Assessment programme Randomised controlled trial and parallel economic evaluation of conventional ventilatory support versus extracorporeal membrane oxygenation for severe adult respiratory failure (CESAR)
2010     NIHR Health Technology Assessment programme Randomised controlled trial and parallel economic evaluation of conventional ventilatory support versus extracorporeal membrane oxygenation for severe adult respiratory failure (CESAR)
2017     NIHR Health Technology Assessment programme Randomised controlled trial evaluating the effectiveness and cost-effectiveness of 'Families for Health', a family-based childhood obesity treatment intervention delivered in a community setting for ages 6 to 11 years
2017     NIHR Health Technology Assessment programme Randomised controlled trial evaluating the effectiveness and cost-effectiveness of 'Families for Health', a family-based childhood obesity treatment intervention delivered in a community setting for ages 6 to 11 years
2000     NIHR Health Technology Assessment programme Randomised controlled trial of non-directive counselling, cognitive-behaviour therapy and usual general practitioner care in the management of depression as well as mixed anxiety and depression in primary care
2017     NIHR Health Technology Assessment programme Randomised controlled trial of silk therapeutic garments for the management of atopic eczema in children: the CLOTHES trial
2017     NIHR Health Technology Assessment programme Randomised controlled trial of silk therapeutic garments for the management of atopic eczema in children: the CLOTHES trial
2005     NIHR Health Technology Assessment programme Randomised controlled trial of the cost-effectiveness of water-based therapy for lower limb osteoarthritis
2009     NIHR Health Technology Assessment programme Randomised controlled trial of the use of the three dressing preparations in the management of chronic ulceration of the foot in diabetes
2014     NIHR Health Technology Assessment programme Randomised controlled trial of Tumour necrosis factor inhibitors Against Combination Intensive Therapy with conventional disease-modifying antirheumatic drugs in established rheumatoid arthritis: the TACIT trial and associated systematic reviews
2009     NIHR Health Technology Assessment programme Randomised controlled trial to determine the clinical and cost-effectiveness of selective serotonin reuptake inhibitors plus supportive care, versus supportive care alone, for mild to moderate depression with somatic symptoms in primary care. The THREAD (THREshold for AntiDepressant response) study
2010     NIHR Health Technology Assessment programme Randomised controlled trials for policy interventions: a review of reviews and meta-regression
2006     NIHR Health Technology Assessment programme Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment
2005     NIHR Health Technology Assessment programme Randomised evaluation of alternative electrosurgical modalities to treat bladder outflow obstruction in men with benign prostatic hyperplasia
2009     NIHR Health Technology Assessment programme Randomised preference trial of medical versus surgical termination of pregnancy less than 14 weeks' gestation (TOPS)
2008     NIHR Health Technology Assessment programme Randomised trial of fluoxetine and cognitive-behavioral therapy versus fluoxetine alone in adolescents with persistent major depression - primary research
2005     Agency for Healthcare Research and Quality (AHRQ) Randomized trials of secondary prevention programs in coronary artery disease: a systematic review
2015     NIHR Horizon Scanning Centre (NIHR HSC) Ranibizumab (Lucentis) for choroidal neovascularisation and macular oedema
2009     NIHR Horizon Scanning Centre (NIHR HSC) Ranibizumab (Lucentis) for diabetic macular oedema
2009     NIHR Horizon Scanning Centre (NIHR HSC) Ranibizumab (Lucentis) for macular oedema secondary to central or branch retinal vein occlusion
2008     HAYES, Inc. Ranibizumab (Lucentis) for neovascular age-related macular degeneration
2011     NIHR Horizon Scanning Centre (NIHR HSC) Ranibizumab (Lucentis) for visual impairment due to choroidal neovascularisation (CNV) secondary to pathological myopia - first line
2008     NIHR Health Technology Assessment programme Ranibizumab and pegaptanib for the treatment of age-related macular degeneration - technology assessment report for NICE, ref 04/24/01
2008     NIHR Health Technology Assessment programme Ranibizumab and pegaptanib for the treatment of age-related macular degeneration: a systematic review and economic evaluation
2005     NIHR Horizon Scanning Centre (NIHR HSC) Ranibizumab for age-related macular degeneration - horizon scanning review
2013     NIHR Health Technology Assessment programme Ranibizumab for the treatment of choroidal neovascularisation associated with pathological myopia
2011     NIHR Health Technology Assessment programme Ranibizumab for the treatment of diabetic macular oedema
2011     NIHR Health Technology Assessment programme Ranibizumab for the treatment of macular oedema caused by retinal vein occlusion (RVO): a single technology appraisal
2015     Medical Services Advisory Committee (MSAC) Ranibizumab for the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (RVO)
2022     Agency for Care Effectiveness (ACE) Ranibizumab for treating age-related macular degeneration, diabetic macular oedema and retinal vein occlusion
2008     The Swedish Council on Health Technology Assessment (SBU) Ranibizumab in treating age-related macular degeneration
2014     Andalusian Health Technology Assessment Area (AETSA) Ranizumab and bevacizumab for the treatment of diabetic macular oedema.
2003     University HealthSystem Consortium (UHC) Ranolazine
2007     Canadian Agency for Drugs and Technologies in Health (CADTH) Ranolazine (Ranexa (TM)) for chronic stable angina
2010     All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Ranolazine (Ranexa®)
2009     All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Ranolazine (Ranexa®) as add-on therapy for symptomatic treatment of stable angina pectoris
2004     Canadian Coordinating Office for Health Technology Assessment (CCOHTA) Ranolazine for the treatment of stable angina
2002     NIHR Horizon Scanning Centre (NIHR HSC) Ranpirnase for mesothelioma - horizon scanning review
2008     Agenzia nazionale per i servizi sanitari regionali (Agenas) Rapid (bed-side) tests for influenza
2007     HAYES, Inc. Rapid antibody testing for HIV
2011     HAYES, Inc. Rapid antibody tests for HIV screening
2020     Health Technology Wales (HTW) Rapid antigen detecting tests for diagnosing group A streptococcal infections in the community pharmacy setting
2020     NIHR Health Technology Assessment programme Rapid antigen detection and molecular tests for group A streptococcal infections for acute sore throat: systematic reviews and economic evaluation
2021     Health Information and Quality Authority (HIQA) Rapid antigen testing for screening or surveillance of asymptomatic individuals to limit transmission of SARS-CoV-2
2008     Belgian Health Care Knowledge Centre (KCE) Rapid assessment of a selection of new treatments for prostate cancer and benign prostate hypertrophy
2006     Belgian Health Care Knowledge Centre (KCE) Rapid assessment of emerging spine technologies: intervertebral disc replacement and vertebro/balloon kyphoplasty
2014     Malaysian Health Technology Assessment (MaHTAS) Rapid blood test device for HIV, HBV, HCV, & syphillis
2008     Adelaide Health Technology Assessment (AHTA) Rapid breath test for assessing total body water in chronic kidney disease patients
1999     Alberta Heritage Foundation for Medical Research (AHFMR) Rapid cholesterol test
2020     European Network for Health Technology Assessment (EUnetHTA) Rapid collaborative review on the current role of antibody tests for novel coronavirus SARS-COV-2 in the management of the pandemic
2020     European Network for Health Technology Assessment (EUnetHTA) Rapid collaborative review on the diagnostic accuracy of molecular methods that detect the presence of SARS-COV-2 virus in people with suspected COVID-19
2020     Health Technology Wales (HTW) Rapid collaborative review on the diagnostic accuracy of molecular methods that detect the presence of the SARS-COV-2 virus in people with suspected COVID-19
2015     NIHR Health Technology Assessment programme Rapid detection of health-care-associated bloodstream infection in critical care using multipathogen real-time polymerase chain reaction technology: a diagnostic accuracy study and systematic review
2023     NIHR Health and Social Care Delivery Program Rapid evaluation of service innovations in health and social care: key considerations
2023     NIHR Health Services and Delivery Research programme Rapid evaluation of the Special Measures for Quality and challenged provider regimes: a mixed-methods study